Product Center
Monkeypox mRNA vaccine receives approval for submission, collaborating with Chongqing CDC to enhance innovation capabilities
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-04-01
- Views:
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. JS has achieved multiple groundbreaking advancements in corporate innovation and development. The clinical trial application for its independently developed Category I new drug, the monkeypox mRNA vaccine, has been accepted by the Drug Evaluation Center of the National Medical Products Administration of China. Meanwhile, the company has officially partnered with the Chongqing Municipal Center for Disease Control and Prevention (Chongqing Academy of Preventive Medicine) as a strategic collaborator, jointly ushering in a new chapter of coordinated development in public health services and the biopharmaceutical industry.
Monkeypox mRNA vaccine receives approval for submission, collaborating with Chongqing CDC to enhance innovation capabilities
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. JS has achieved multiple groundbreaking advancements in corporate innovation and development. The clinical trial application for its independently developed Category I new drug, the monkeypox mRNA vaccine, has been accepted by the Drug Evaluation Center of the National Medical Products Administration of China. Meanwhile, the company has officially partnered with the Chongqing Municipal Center for Disease Control and Prevention (Chongqing Academy of Preventive Medicine) as a strategic collaborator, jointly ushering in a new chapter of coordinated development in public health services and the biopharmaceutical industry.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-04-01 11:24
- Views:
Recently, Ab&B Bio-Tech Co., Ltd. JS has achieved multiple groundbreaking advancements in corporate innovation and development. The clinical trial application for its independently developed Category I new drug, the monkeypox mRNA vaccine, has been accepted by the Drug Evaluation Center of the National Medical Products Administration of China. Meanwhile, the company has officially partnered with the Chongqing Municipal Center for Disease Control and Prevention (Chongqing Academy of Preventive Medicine) as a strategic collaborator, jointly ushering in a new chapter of coordinated development in public health services and the biopharmaceutical industry.
After obtaining clinical trial approval from the US FDA, the monkeypox mRNA vaccine has made significant progress again - its clinical trial application has been officially accepted by the Drug Evaluation Center of the China National Medical Products Administration, becoming the first monkeypox mRNA vaccine accepted in China. This milestone is not only a further verification of the company's product research and development capabilities, but also a strong affirmation of Ab&B Bio's mRNA technology platform capabilities, marking the company's solid ability to contribute Chinese strength to global public health prevention and control.
The continuous output of innovative achievements is attributed to the mRNA technology platform built by the company's doctoral team at home and abroad. The core advantage of this platform lies in its agility in research and development and the potential for large-scale production. As a "digital" platform, once the target sequence is obtained, it can be quickly designed and synthesized, achieving rapid iteration. On a safety level, mRNA does not enter the nucleus and there is no risk of genome integration. At the efficiency level, through sequence optimization and advanced delivery systems, it can simultaneously activate strong humoral and cellular immunity.
At present, the company has completed the technological accumulation in the development of mRNA vaccines for single pathogens in the field of infectious disease vaccines, and will rapidly expand to the development of combined vaccines for multiple pathogens and innovative cancer therapies using mRNA technology. In addition, the company actively utilizes AI technology to empower the mRNA technology platform, helping to improve the quality and efficiency of research and development.
At present, the company has completed the technological accumulation in the development of mRNA vaccines for single pathogens in the field of infectious disease vaccines, and will rapidly expand to the development of combined vaccines for multiple pathogens and innovative cancer therapies using mRNA technology. In addition, the company actively utilizes AI technology to empower the mRNA technology platform, helping to improve the quality and efficiency of research and development.
As the disease control institution that discovered and handled the first imported monkeypox case in mainland China, the Chongqing Center for Disease Control and Prevention has leading technical reserves and practical experience in virus tracing, monitoring and early warning, and emergency response to sudden infectious diseases nationwide. Previously, Ab&B Bio had jointly administered the quadrivalent influenza virus subunit vaccine (HRK-X®) to pregnant women at the First Affiliated Hospital of Chongqing Medical University and the Yuzhong District Center for Disease Control and Prevention in Chongqing. We have established a deep friendship with Chongqing CDC in the research project on safety and immune efficacy. This strategic partnership will further expand the dimensions of cooperation and upgrade from "point projects" to "systematic collaboration".
In the future, both sides will rely on their respective advantages in scientific research innovation, clinical research, and industrial transformation, deepen scientific research project cooperation in key areas such as infectious disease prevention, diagnosis, and treatment, promote the construction of innovative vaccine research and application technology platforms, strengthen the construction of biosafety laboratories and related project cooperation, promote the transformation of cutting-edge technological achievements, and provide strong support for the high-quality development of public health.
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
